Appointments: Eli Lilly, Cell Medica, Exscientia, Achaogen, Eyevensys, Tessa Therapeutics, EMD Serono, TapImmune, Cue Biopharma

Eli Lilly & Co. has announced that Kimberly Blackwell will join Lilly Oncology as vice president of early phase development and immuno-oncology in March 2018. She is currently professor of medicine and assistant professor of radiation oncology at Duke University Medical Center where she has played a major role in developing therapies that represent non-chemotherapy based approaches for treating breast cancer. She also made Time magazine's '100 Most Influential People in the World' list in 2013.

The UK's Cell Medica Ltd. has announced the appointment of Annalisa Jenkins, as chair of its board of directors, replacing Thomas Hecht. Prior to joining Cell Medica, she served as CEO of Dimension Therapeutics, a gene therapy company acquired by Ultragenyx Pharmaceutical in November 2017 and has held a number of high-profile posts in the industry, notably as head of global R&D at Merck Serono